Table 4.
Summary of trials exploring regiments treated for adult LCH patients
| Year | Author | patient number | Fisrt line regimen | Overall response rate | PFS or reactivation | 3–4 grade hematological toxicity |
|---|---|---|---|---|---|---|
| 1999 | Alan Saven | 13 | Cladribine | 75% | N/A | Neutropenia 7/13 (53.8%) |
| 2012 | Maria A. Cantu | 19 | Vinblastine+ prednisone | 16% | N/A | 75% |
| 22 | 2-CdA | 41% | N/A | 37% | ||
| 24 | ARA-C | 79% | N/A | 20% | ||
| 2013 | Z. ADAM | 7 | Cladribine | 86% | N/A | Neutropenia 6/7 (86%) |
| 2015 | Enrico Derenzini | 11 | MACOP-B | 100% | Overall 64% | Neutropenia 4/11 (36.4%) |
| 2016 | Duan MH | 31 | CEVP | 68.8% | Reactivation rate 73.3% |
Neutropenia 35.6% Thrombocytopenia 8.9% |
| 14 | VP | 70% | Reactivation rate 71% |
Neutropenia 48.4% Thrombocytopenia 12.9% |
N/A Not Applicable, MACOP-B cyclophosphamide, doxorubicin, methotrexate, vincristine, bleomycin, prednisone, CEVP cyclophosphamide, vindesine, etoposide, prednisone, VP vindesine, prednisone